Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Outcomes in COVID-19 favipiravir studies
00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlUdwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Sawanpanyalert68%0.32 [0.15-0.66]progressionn/an/aTau​2 = 0.00; I​2 = 0.0%Early treatment48%0.52 [0.36-0.76]4/2314/17948% improvementCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Shinkai (SB RCT)37%0.63 [0.40-0.98]imp. time107 (n)49 (n)Alotaibi57%0.43 [0.18-1.01]death244 (n)193 (n)OT​1Tau​2 = 0.08; I​2 = 61.3%Late treatment26%0.74 [0.57-0.95]154/902153/1,67626% improvementAll studies32%0.68 [0.54-0.86]158/1,133157/1,85532% improvement13 favipiravir COVID-19 studiesc19favipiravir.com Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.08; I​2 = 57.0%; Z = 3.21Effect extraction pre-specifiedFavors favipiravirFavors control 00.250.50.7511.251.51.752+Dabbous (RCT)45%0.55 [0.05-5.81]1/442/48Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment45%0.55 [0.05-5.81]1/442/4845% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]26/19021/183OT​1Improvement, RR [CI]TreatmentControlAghajani26%0.74 [0.43-1.27]40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]33/11024/116Alotaibi57%0.43 [0.18-1.01]244 (n)193 (n)OT​1Tau​2 = 0.13; I​2 = 61.0%Late treatment7%0.93 [0.59-1.47]59/58445/1,4437% improvementAll studies8%0.92 [0.60-1.41]60/62847/1,4918% improvement5 favipiravir COVID-19 mortality resultsc19favipiravir.com Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.11; I​2 = 49.7%; Z = 0.38Favors favipiravirFavors control 00.250.50.7511.251.51.752+Solaymani-.. (RCT)-19%1.19 [0.73-1.94]31/19025/183OT​1Improvement, RR [CI]TreatmentControlAlmoosa-90%1.90 [1.11-3.26]110 (n)116 (n)Tau​2 = 0.04; I​2 = 36.1%Late treatment-48%1.48 [0.94-2.33]31/30025/299-48% improvementAll studies-48%1.48 [0.94-2.33]31/30025/299-48% improvement2 favipiravir COVID-19 ICU resultsc19favipiravir.com Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.04; I​2 = 36.1%; Z = 1.70Favors favipiravirFavors control 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlDabbous (RCT)16%0.84 [0.69-1.01]hosp. time44 (n)48 (n)Tau​2 = 0.00; I​2 = 0.0%Early treatment16%0.84 [0.70-1.01]3/1562/10416% improvementIvashchenko (RCT)-300%4.00 [0.20-79.6]hosp.2/400/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-300%4.00 [0.20-79.6]2/400/20-300% improvementAll studies16%0.84 [0.70-1.01]5/1962/12416% improvement3 favipiravir COVID-19 hospitalization resultsc19favipiravir.com Oct 17, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.81Favors favipiravirFavors control 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlDabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Sawanpanyalert68%0.32 [0.15-0.66]progressionn/an/aTau​2 = 0.00; I​2 = 0.0%Early treatment61%0.39 [0.20-0.75]4/1564/10461% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Improvement, RR [CI]TreatmentControlAghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Alotaibi57%0.43 [0.18-1.01]death244 (n)193 (n)OT​1Tau​2 = 0.13; I​2 = 61.0%Late treatment7%0.93 [0.59-1.47]59/58445/1,4437% improvementAll studies24%0.76 [0.48-1.21]63/74049/1,54724% improvement7 favipiravir COVID-19 serious outcomesc19favipiravir.com Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.21; I​2 = 61.9%; Z = 1.15Effect extraction pre-specifiedFavors favipiravirFavors control 00.250.50.7511.251.51.752+Ruzhentsova (RCT)22%0.78 [0.92-1.79]viral+112 (n)56 (n)Improvement, RR [CI]TreatmentControlUdwadia (RCT)29%0.71 [0.46-1.10]viral time75 (n)75 (n)Tau​2 = 0.00; I​2 = 0.0%Early treatment25%0.75 [0.57-0.99]0/1870/13125% improvementCai71%0.29 [0.10-0.86]viral+35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Pushkar (RCT)90%0.10 [0.02-0.40]viral+2/10021/100Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Tau​2 = 0.16; I​2 = 46.0%Late treatment65%0.35 [0.20-0.64]24/21144/18465% improvementAll studies48%0.52 [0.35-0.77]24/39844/31548% improvement6 favipiravir COVID-19 viral clearance resultsc19favipiravir.com Oct 17, 2021Tau​2 = 0.12; I​2 = 58.1%; Z = 3.30Favors favipiravirFavors control 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlUdwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment39%0.61 [0.40-0.95]4/2314/17939% improvementIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Improvement, RR [CI]TreatmentControlPushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Shinkai (SB RCT)37%0.63 [0.40-0.98]imp. time107 (n)49 (n)Tau​2 = 0.06; I​2 = 59.1%Late treatment28%0.72 [0.55-0.96]121/473129/37128% improvementAll studies28%0.72 [0.57-0.89]125/704133/55028% improvement8 favipiravir COVID-19 Randomized Controlled Trialsc19favipiravir.com Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.03; I​2 = 38.3%; Z = 2.97Effect extraction pre-specifiedFavors favipiravirFavors control 00.250.50.7511.251.51.752+Dabbous (RCT)45%0.55 [0.05-5.81]1/442/48Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment45%0.55 [0.05-5.81]1/442/4845% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]26/19021/183OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-19%1.19 [0.70-2.04]26/19021/183-19% improvementAll studies-15%1.15 [0.68-1.94]27/23423/231-15% improvement2 favipiravir COVID-19 RCT mortality resultsc19favipiravir.com Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.51Favors favipiravirFavors control 00.250.50.7511.251.51.752+Udwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Improvement, RR [CI]TreatmentControlDabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Sawanpanyalert68%0.32 [0.15-0.66]progressionn/an/aTau​2 = 0.00; I​2 = 0.0%Early treatment49%0.51 [0.34-0.75]1/1192/12349% improvementCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Shinkai (SB RCT)37%0.63 [0.40-0.98]imp. time107 (n)49 (n)Alotaibi57%0.43 [0.18-1.01]death244 (n)193 (n)OT​1Tau​2 = 0.14; I​2 = 63.4%Late treatment31%0.69 [0.49-0.97]81/80268/1,57631% improvementAll studies36%0.64 [0.48-0.85]82/92170/1,69936% improvement11 favipiravir COVID-19 peer reviewed trialsc19favipiravir.com Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.13; I​2 = 58.4%; Z = 3.03Effect extraction pre-specifiedFavors favipiravirFavors control 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlRuzhentsova (RCT)39%0.61 [0.43-0.88]no recov.112 (n)56 (n)Ruzhentsova (RCT)22%0.78 [0.92-1.79]viral+112 (n)56 (n)Udwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Udwadia (RCT)29%0.71 [0.46-1.10]viral time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Dabbous (RCT)88%0.12 [0.01-2.08]ventilation0/444/48Dabbous (RCT)16%0.84 [0.69-1.01]hosp. time44 (n)48 (n)Sawanpanyalert68%0.32 [0.15-0.66]progressionn/an/aCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Cai71%0.29 [0.10-0.86]viral+35 (n)45 (n)Ivashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Ivashchenko (RCT)62%0.38 [0.09-1.52]viral+3/404/20Ivashchenko (RCT)-67%1.67 [0.52-5.39]no disch.10/403/20Ivashchenko (RCT)-300%4.00 [0.20-79.6]hosp.2/400/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Pushkar (RCT)33%0.67 [0.54-0.82]recov. time100 (n)100 (n)Pushkar (RCT)45%0.55 [0.42-0.72]no recov.40/10073/100Pushkar (RCT)20%0.80 [0.64-1.00]recov. time100 (n)100 (n)Pushkar (RCT)70%0.30 [0.16-0.58]no disch.10/10033/100Pushkar (RCT)27%0.73 [0.63-0.86]no recov.66/10090/100Pushkar (RCT)33%0.67 [0.50-0.89]pneumonia40/10060/100Pushkar (RCT)90%0.10 [0.02-0.40]viral+2/10021/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Solaymani-.. (RCT)-53%1.53 [0.86-2.71]ventilation27/19017/183OT​1Solaymani-.. (RCT)-19%1.19 [0.73-1.94]ICU31/19025/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Zhao (RCT)52%0.48 [0.25-0.91]viral time36 (n)19 (n)Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Almoosa-90%1.90 [1.11-3.26]ICU110 (n)116 (n)Almoosa-11%1.11 [0.96-1.29]recov. time110 (n)116 (n)Shinkai (SB RCT)37%0.63 [0.40-0.98]imp. time107 (n)49 (n)Shinkai (SB RCT)59%0.41 [0.18-0.93]imp. time47 (n)13 (n)Alotaibi57%0.43 [0.18-1.01]death244 (n)193 (n)OT​1favipiravir COVID-19 outcomesc19favipiravir.com Oct 17, 2021Favors favipiravirFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit